Naftopidil - Wikipedia
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hyperplasia which acts as a selective α 1 -adrenergic receptor antagonist or alpha-1 blocker. [1] The reaction of 1-naphthol (1) with epichlorohydrin (2) in …
萘哌地尔 - 百度百科
萘哌地尔，是一种有机化合物，化学式为C24H28N2O3，主要用作α1肾上腺素受体阻滞药，能够抑制α1受体引起的血压上升，并兼有钙离子拮抗作用，药效学试验表明，本品对多种高血压动物模型有降压作用，降压持续时间长，降压时不引起反射性心动过速，多次口服给药未见明显的首剂效应和耐药现象。 那妥萘哌地尔是一种新型的长效、高选择性的α1-受体阻滞剂，通过选择性地作用于α1A和α1D受体，能够缓解该受体兴奋所致的前列腺和尿道的交感神经性紧张、降低尿道内 …
Naftopidil: Uses, Interactions, Mechanism of Action - DrugBank …
2016年10月20日 · Naftopidil has been investigated for the treatment of Disorder of Urinary Stent.
Naftopidil for the treatment of lower urinary tract symptoms …
2018年10月11日 · Naftopidil compared to propiverine (anticholinergic) for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia (short term) Participants: men with lower urinary tract symptoms suggesting benign prostatic hyperplasia Setting: likely outpatients Intervention: naftopidil Comparator: propiverine: Outcomes № of ...
萘哌地尔(Naftopidil) - 药物靶点：ADRA1_在研适应症：排尿困 …
Anticholinergics or beta3-adrenergic receptor agonists to treat overactive bladder in patients receiving tamsulosin and naftopidil was strongly associated with delirium.
Naftopidil - Indications, Dosage, Side Effects and Precautions - Medindia
2024年11月8日 · Naftopidil is a selective α1-adrenergic receptor antagonist or alpha blocker. Naftopidil is prescribed in Japan for the treatment of benign prostatic hyperplasia (BPH) and...
NAFTOPIDIL - National Center for Advancing Translational Sciences
Naftopidil (INN, marketed under the brand name Flivas) is a drug used in benign prostatic hypertrophy which acts as a selective alpha1-adrenergic receptor antagonist, has been used for the treatment of benign prostatic obstruction and benign prostatic hyperplasia (BPH) associated lower urinary tract symptoms (LUTS).
Naftopidil - an overview | ScienceDirect Topics
Naftopidil is a potent postsynaptic-selective alpha-1-antagonist that was launched for the treatment of dysuria associated with benign prostatic hypertrophy.
Clinical Efficacy and Safety of Naftopidil Treatment for Patients …
2017年7月1日 · To investigate the efficacy and safety of naftopidil for benign prostatic hyperplasia (BPH) patients, mainly focusing on changes in blood pressure (BP). Of a total of 118 patients, 90 normotensive (NT) and 28 hypertensive (HT) patients were randomly assigned to be treated with naftopidil 50 mg or 75 mg for 12 weeks, once-daily.
Naftopidil | C24H28N2O3 | CID 4418 - PubChem
Naftopidil | C24H28N2O3 | CID 4418 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.